Sight Sciences, Inc. (SGHT) Financial Analysis & Valuation | Quarter Chart
Sight Sciences, Inc. (SGHT)
SGHTPrice: $3.67
Fair Value: 🔒
🔒score
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduc... more
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercia... more
Description
Shares
| Market Cap | $198.20M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Paul Badawi |
| IPO Date | 2021-07-15 | CAGR | 0.39% |
| Employees | 216 | Website | www.sightsciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SGHT chart loading...
Fundamentals
Technicals
| Enterprise Value | $358.11M | P/E Ratio | -4.96 |
| Forward P/E | -6.88 | PEG Ratio | — |
| P/S Ratio | 2.1 | P/B Ratio | 2.55 |
| P/CF Ratio | -5.49 | P/FCF Ratio | -5.44 |
| EPS | $-0.74 | EPS Growth 1Y | -27.18% |
| EPS Growth 3Y | -58.33% | EPS Growth 5Y | -24.24% |
| Revenue Growth 1Y | -3.13% | Gross Margin | 0.86% |
| Operating Margin | -0.48% | Profit Margin | -0.5% |
| ROE | -0.56% | ROA | -0.33% |
| ROCE | -0.36% | Current Ratio | 10.22 |
| Quick Ratio | 9.52 | Cash Ratio | 8.34 |
| Debt/Equity | 0.63 | Interest Coverage | -14.47 |
| Altman Z Score | -0.71 | Piotroski Score | 4 |